• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BA.1、BA.2 和 BA.2.75 变异株显示出相当的复制动力学,对上皮屏障的影响降低,并引起交叉中和抗体。

BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies.

机构信息

Bioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.

INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.

出版信息

PLoS Pathog. 2023 Feb 24;19(2):e1011196. doi: 10.1371/journal.ppat.1011196. eCollection 2023 Feb.

DOI:10.1371/journal.ppat.1011196
PMID:36827451
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9994724/
Abstract

The Omicron variant of SARS-CoV-2 is capable of infecting unvaccinated, vaccinated and previously-infected individuals due to its ability to evade neutralization by antibodies. With multiple sub-lineages of Omicron emerging in the last 12 months, there is inadequate information on the quantitative antibody response generated upon natural infection with Omicron variant and whether these antibodies offer cross-protection against other sub-lineages of Omicron variant. In this study, we characterized the growth kinetics of Kappa, Delta and Omicron variants of SARS-CoV-2 in Calu-3 cells. Relatively higher amounts infectious virus titers, cytopathic effect and disruption of epithelial barrier functions was observed with Delta variant whereas infection with Omicron sub-lineages led to a more robust induction of interferon pathway, lower level of virus replication and mild effect on epithelial barrier. The replication kinetics of BA.1, BA.2 and BA.2.75 sub-lineages of the Omicron variant were comparable in cell culture and natural infection in a subset of individuals led to a significant increase in binding and neutralizing antibodies to the Delta variant and all the three sub-lineages of Omicron but the level of neutralizing antibodies were lowest against the BA.2.75 variant. Finally, we show that Cu2+, Zn2+ and Fe2+ salts inhibited in vitro RdRp activity but only Cu2+ and Fe2+ inhibited both the Delta and Omicron variants in cell culture. Thus, our results suggest that high levels of interferons induced upon infection with Omicron variant may counter virus replication and spread. Waning neutralizing antibody titers rendered subjects susceptible to infection by Omicron variants and natural Omicron infection elicits neutralizing antibodies that can cross-react with other sub-lineages of Omicron and other variants of concern.

摘要

新冠病毒奥密克戎变异株由于能够逃避抗体的中和作用,能够感染未接种疫苗、已接种疫苗和既往感染的个体。在过去 12 个月中,奥密克戎出现了多个亚谱系,关于奥密克戎变异株自然感染产生的定量抗体反应,以及这些抗体是否对奥密克戎变异株的其他亚谱系提供交叉保护,信息不足。在这项研究中,我们在 Calu-3 细胞中表征了新冠病毒的 Kappa、Delta 和奥密克戎变异株的生长动力学。与奥密克戎亚谱系相比,Delta 变异株导致更高的感染性病毒滴度、细胞病变效应和上皮屏障功能破坏。而奥密克戎亚谱系感染导致干扰素通路更强烈的诱导、病毒复制水平更低,对上皮屏障的影响也更温和。奥密克戎变异株的 BA.1、BA.2 和 BA.2.75 亚谱系在细胞培养中的复制动力学相当,在个体的亚组中,自然感染导致针对 Delta 变异株和奥密克戎的所有三个亚谱系的结合和中和抗体显著增加,但针对 BA.2.75 变异株的中和抗体水平最低。最后,我们表明 Cu2+、Zn2+和 Fe2+盐抑制 RdRp 活性,但只有 Cu2+和 Fe2+在细胞培养中抑制 Delta 和奥密克戎变异株。因此,我们的结果表明,奥密克戎变异株感染诱导高水平的干扰素可能会对抗病毒复制和传播。中和抗体滴度的下降使宿主易感染奥密克戎变异株,而自然奥密克戎感染会产生可与其他奥密克戎亚谱系和其他关注变异株交叉反应的中和抗体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/17154ef147ab/ppat.1011196.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/dd71936f96ce/ppat.1011196.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/b8dbcf4a88a7/ppat.1011196.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/76b425d6fda9/ppat.1011196.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/c25a69f6b6c4/ppat.1011196.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/a85064ca45e2/ppat.1011196.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/86300448125f/ppat.1011196.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/17154ef147ab/ppat.1011196.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/dd71936f96ce/ppat.1011196.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/b8dbcf4a88a7/ppat.1011196.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/76b425d6fda9/ppat.1011196.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/c25a69f6b6c4/ppat.1011196.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/a85064ca45e2/ppat.1011196.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/86300448125f/ppat.1011196.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cca/9994724/17154ef147ab/ppat.1011196.g007.jpg

相似文献

1
BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies.BA.1、BA.2 和 BA.2.75 变异株显示出相当的复制动力学,对上皮屏障的影响降低,并引起交叉中和抗体。
PLoS Pathog. 2023 Feb 24;19(2):e1011196. doi: 10.1371/journal.ppat.1011196. eCollection 2023 Feb.
2
Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.初次感染 SARS-CoV-2 奥密克戎 BA.1 和 BA.2 株后中和抗体的不同反应特征
Front Immunol. 2022 Jul 19;13:946318. doi: 10.3389/fimmu.2022.946318. eCollection 2022.
3
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.奥密克戎变异株疫苗突破性感染诱导针对 SARS-CoV-2 奥密克戎 BA.1 的交叉中和反应优于单独感染。
Int J Mol Sci. 2022 Jul 12;23(14):7675. doi: 10.3390/ijms23147675.
4
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.中和 SARS-CoV-2 奥密克戎亚谱系 BA.1、BA.1.1 和 BA.2.
Cell Host Microbe. 2022 Aug 10;30(8):1093-1102.e3. doi: 10.1016/j.chom.2022.04.014. Epub 2022 Apr 25.
5
Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.接种疫苗和奥密克戎 BA.1/BA.2 感染恢复期增强了针对 BA.4/5 的系统性但非黏膜免疫。
Microbiol Spectr. 2023 Jun 15;11(3):e0516322. doi: 10.1128/spectrum.05163-22. Epub 2023 Apr 26.
6
Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.中国天津地区针对 SARS-CoV-2 奥密克戎 BA.1 变异株疫苗突破性感染后五种 SARS-CoV-2 变异株的中和抗体反应和 T 淋巴细胞变化的前瞻性研究。
Biomed Environ Sci. 2023 Jul 20;36(7):614-624. doi: 10.3967/bes2023.047.
7
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants.BA.2 和 BA.5 奥密克戎在免疫学上与 BA.1 奥密克戎和前奥密克戎变体不同。
Nat Commun. 2022 Dec 13;13(1):7701. doi: 10.1038/s41467-022-35312-3.
8
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.发现并经鼻腔给药的一种 SARS-CoV-2 广谱中和抗体,对多种奥密克戎亚变种具有活性。
Med. 2022 Oct 14;3(10):705-721.e11. doi: 10.1016/j.medj.2022.08.002. Epub 2022 Aug 8.
9
Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.COVID-19 患者在突破感染 SARS-CoV-2 变异株 Delta、Omicron-BA.1 和 Omicron-BA.5 期间的免疫反应。
Front Immunol. 2023 Jul 13;14:1150667. doi: 10.3389/fimmu.2023.1150667. eCollection 2023.
10
Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021.2021 年 1 月至 3 月采集的供体血浆中对 SARS-CoV-2 奥密克戎 BA.1 的中和能力降低。
Microbiol Spectr. 2023 Aug 17;11(4):e0525622. doi: 10.1128/spectrum.05256-22. Epub 2023 Jun 8.

引用本文的文献

1
BharatSim: An agent-based modelling framework for India.巴拉特模拟:一个针对印度的基于智能体的建模框架。
PLoS Comput Biol. 2024 Dec 30;20(12):e1012682. doi: 10.1371/journal.pcbi.1012682. eCollection 2024 Dec.
2
The effects of iron deficient and high iron diets on SARS-CoV-2 lung infection and disease.缺铁和高铁饮食对新型冠状病毒肺炎肺部感染及疾病的影响。
Front Microbiol. 2024 Sep 4;15:1441495. doi: 10.3389/fmicb.2024.1441495. eCollection 2024.
3
Replication kinetics and infectivity of SARS-CoV-2 Omicron variant sublineages recovered in the Republic of Korea.

本文引用的文献

1
Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants.奥密克戎亚变种增强的先天免疫抑制作用的进化。
Nat Microbiol. 2024 Feb;9(2):451-463. doi: 10.1038/s41564-023-01588-4. Epub 2024 Jan 16.
2
Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates.SARS-CoV-2 奥密克戎 BA.2.75 临床分离株的特征。
Nat Commun. 2023 Mar 23;14(1):1620. doi: 10.1038/s41467-023-37059-x.
3
Omicron BA.2 lineage predominance in severe acute respiratory syndrome coronavirus 2 positive cases during the third wave in North India.
在大韩民国分离出的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变异亚谱系的复制动力学和传染性
Osong Public Health Res Perspect. 2024 Jun;15(3):260-264. doi: 10.24171/j.phrp.2023.0216. Epub 2024 Jun 27.
4
Mathematical model explains differences in Omicron and Delta SARS-CoV-2 dynamics in Caco-2 and Calu-3 cells.数学模型解释了奥密克戎和德尔塔 SARS-CoV-2 在 Caco-2 和 Calu-3 细胞中的动力学差异。
PeerJ. 2024 Mar 27;12:e16964. doi: 10.7717/peerj.16964. eCollection 2024.
5
Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue.奥密克戎刺突蛋白赋予了 SARS-CoV-2 更强的在人鼻腔组织中的感染性和干扰素抗性。
Nat Commun. 2024 Jan 30;15(1):889. doi: 10.1038/s41467-024-45075-8.
6
Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemia.奥密克戎变异株感染儿童急性白血病的临床特征。
Ann Hematol. 2024 Mar;103(3):729-736. doi: 10.1007/s00277-023-05593-9. Epub 2023 Dec 28.
7
Comparative Computational Analysis of Spike Protein Structural Stability in SARS-CoV-2 Omicron Subvariants.比较 SARS-CoV-2 奥密克戎亚变种刺突蛋白结构稳定性的计算分析。
Int J Mol Sci. 2023 Nov 8;24(22):16069. doi: 10.3390/ijms242216069.
8
A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants.一类新型广谱活性位点定向 3C 样蛋白酶抑制剂,对高度免疫逃逸的 SARS-CoV-2 奥密克戎亚变种具有纳摩尔抗病毒活性。
Emerg Microbes Infect. 2023 Dec;12(2):2246594. doi: 10.1080/22221751.2023.2246594.
9
Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue.奥密克戎刺突蛋白赋予严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在人鼻组织中更强的传染性和干扰素抗性。
bioRxiv. 2023 Oct 12:2023.05.06.539698. doi: 10.1101/2023.05.06.539698.
在印度北部第三波疫情期间,严重急性呼吸综合征冠状病毒2阳性病例中奥密克戎BA.2谱系占主导地位。
Front Med (Lausanne). 2022 Nov 2;9:955930. doi: 10.3389/fmed.2022.955930. eCollection 2022.
4
Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections.野生型 SARS-CoV-2 疫苗的抗原性错误导致 BA.2 突破感染对 BA.4/5/2.75 亚系的交叉中和作用较差。
Nat Commun. 2022 Nov 19;13(1):7120. doi: 10.1038/s41467-022-34400-8.
5
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.奥密克戎 BA.2.75 变异株的病毒学特征。
Cell Host Microbe. 2022 Nov 9;30(11):1540-1555.e15. doi: 10.1016/j.chom.2022.10.003. Epub 2022 Oct 18.
6
Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.Omicron BA.2.75 增强的感染力和抗体逃避能力的特征描述。
Cell Host Microbe. 2022 Nov 9;30(11):1527-1539.e5. doi: 10.1016/j.chom.2022.09.018. Epub 2022 Oct 4.
7
Update on the omicron sub-variants BA.4 and BA.5.关于奥密克戎亚变体 BA.4 和 BA.5 的最新信息。
Rev Med Virol. 2023 Jan;33(1):e2391. doi: 10.1002/rmv.2391. Epub 2022 Aug 26.
8
Omicron SARS-CoV-2 epidemic in England during February 2022: A series of cross-sectional community surveys.2022年2月英国奥密克戎株严重急性呼吸综合征冠状病毒2疫情:一系列横断面社区调查
Lancet Reg Health Eur. 2022 Oct;21:100462. doi: 10.1016/j.lanepe.2022.100462. Epub 2022 Jul 28.
9
Dynamics of competing SARS-CoV-2 variants during the Omicron epidemic in England.奥密克戎疫情期间英国竞争 SARS-CoV-2 变体的动态。
Nat Commun. 2022 Jul 28;13(1):4375. doi: 10.1038/s41467-022-32096-4.
10
Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters.与早期严重急性呼吸综合征冠状病毒 2 D614G 变体相比,奥密克戎 BA.1 和 BA.2 亚谱系在叙利亚仓鼠中致病性和传播潜力降低。
J Infect Dis. 2023 May 12;227(10):1143-1152. doi: 10.1093/infdis/jiac276.